{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T03:48:55Z","timestamp":1765079335394},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,11,27]],"date-time":"2017-11-27T00:00:00Z","timestamp":1511740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"AstraZeneca Nordic-Baltic"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s41669-017-0063-y","type":"journal-article","created":{"date-parts":[[2017,11,27]],"date-time":"2017-11-27T09:06:33Z","timestamp":1511773593000},"page":"393-402","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006\u20132014"],"prefix":"10.1007","volume":"2","author":[{"given":"David","family":"Nathanson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugne","family":"Sabale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan W.","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Nystr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Norhammar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urban","family":"Olsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Bodeg\u00e5rd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,11,27]]},"reference":[{"key":"63_CR1","unstructured":"International Diabetes Federation. IDF diabetes atlas. 2014. \n                    http:\/\/www.diabetesatlas.org\/\n                    \n                  . Accessed 15 May 2017."},{"key":"63_CR2","unstructured":"WHO. Global report of diabetes. Geneva: WHO; 2016. \n                    http:\/\/apps.who.int\/iris\/bitstream\/10665\/204871\/1\/9789241565257_eng.pdf\n                    \n                  . Accessed 15 May 2017."},{"issue":"8","key":"63_CR3","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1007\/s00125-016-3971-y","volume":"59","author":"A Norhammar","year":"2016","unstructured":"Norhammar A, Bodegard J, Nystrom T, Thuresson M, Eriksson JW, Nathanson D. Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006\u20132013. Diabetologia. 2016;59(8):1692\u2013701. \n                    https:\/\/doi.org\/10.1007\/s00125-016-3971-y\n                    \n                  .","journal-title":"Diabetologia"},{"issue":"1","key":"63_CR4","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2337\/diacare.27.1.201","volume":"27","author":"RJ Stevens","year":"2004","unstructured":"Stevens RJ, Coleman RL, Adler AI, Stratton IM, Matthews DR, Holman RR. Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. Diabetes Care. 2004;27(1):201\u20137.","journal-title":"Diabetes Care"},{"issue":"7258","key":"63_CR5","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","volume":"321","author":"IM Stratton","year":"2000","unstructured":"Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ (Clin Res Ed). 2000;321(7258):405\u201312.","journal-title":"BMJ (Clin Res Ed)."},{"issue":"11","key":"63_CR6","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.2522\/ptj.20080020","volume":"88","author":"AD Deshpande","year":"2008","unstructured":"Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications. Phys Ther. 2008;88(11):1254\u201364. \n                    https:\/\/doi.org\/10.2522\/ptj.20080020\n                    \n                  .","journal-title":"Phys Ther"},{"issue":"4","key":"63_CR7","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/nejm199807233390404","volume":"339","author":"SM Haffner","year":"1998","unstructured":"Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229\u201334. \n                    https:\/\/doi.org\/10.1056\/nejm199807233390404\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"4","key":"63_CR8","doi-asserted-by":"publisher","first-page":"714","DOI":"10.2337\/dc07-2124","volume":"31","author":"A Juutilainen","year":"2008","unstructured":"Juutilainen A, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Similarity of the impact of type 1 and type 2 diabetes on cardiovascular mortality in middle-aged subjects. Diabetes Care. 2008;31(4):714\u20139. \n                    https:\/\/doi.org\/10.2337\/dc07-2124\n                    \n                  .","journal-title":"Diabetes Care"},{"issue":"15","key":"63_CR9","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1056\/NEJMoa0806359","volume":"359","author":"RR Holman","year":"2008","unstructured":"Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med. 2008;359(15):1565\u201376. \n                    https:\/\/doi.org\/10.1056\/NEJMoa0806359\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"2","key":"63_CR10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000339763","volume":"34","author":"M Eriksson","year":"2012","unstructured":"Eriksson M, Carlberg B, Eliasson M. The disparity in long-term survival after a first stroke in patients with and without diabetes persists: the Northern Sweden MONICA study. Cerebrovasc Dis. 2012;34(2):153\u201360. \n                    https:\/\/doi.org\/10.1159\/000339763\n                    \n                  .","journal-title":"Cerebrovasc Dis."},{"issue":"10","key":"63_CR11","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1007\/s00125-011-2247-9","volume":"54","author":"M Eliasson","year":"2011","unstructured":"Eliasson M, Jansson JH, Lundblad D, Naslund U. The disparity between long-term survival in patients with and without diabetes following a first myocardial infarction did not change between 1989 and 2006: an analysis of 6,776 patients in the Northern Sweden MONICA Study. Diabetologia. 2011;54(10):2538\u201343. \n                    https:\/\/doi.org\/10.1007\/s00125-011-2247-9\n                    \n                  .","journal-title":"Diabetologia"},{"issue":"8","key":"63_CR12","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s40273-015-0268-9","volume":"33","author":"T Seuring","year":"2015","unstructured":"Seuring T, Archangelidi O, Suhrcke M. The economic costs of type 2 diabetes: a global systematic review. Pharmacoeconomics. 2015;33(8):811\u201331. \n                    https:\/\/doi.org\/10.1007\/s40273-015-0268-9\n                    \n                  .","journal-title":"Pharmacoeconomics."},{"issue":"7","key":"63_CR13","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1007\/s00125-002-0858-x","volume":"45","author":"B Jonsson","year":"2002","unstructured":"Jonsson B, Board C-A. Revealing the cost of type II diabetes in Europe. Diabetologia. 2002;45(7):S5\u201312. \n                    https:\/\/doi.org\/10.1007\/s00125-002-0858-x\n                    \n                  .","journal-title":"Diabetologia"},{"issue":"9","key":"63_CR14","doi-asserted-by":"publisher","first-page":"e39513","DOI":"10.1371\/journal.pone.0039513","volume":"7","author":"W Yang","year":"2012","unstructured":"Yang W, Zhao W, Xiao J, Li R, Zhang P, Kissimova-Skarbek K, et al. Medical care and payment for diabetes in China: enormous threat and great opportunity. PLoS ONE. 2012;7(9):e39513. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0039513\n                    \n                  .","journal-title":"PLoS ONE"},{"key":"63_CR15","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2147\/vhrm.s33934","volume":"9","author":"B Ahren","year":"2013","unstructured":"Ahren B. Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. Vasc Health Risk Manag. 2013;9:155\u201363. \n                    https:\/\/doi.org\/10.2147\/vhrm.s33934\n                    \n                  .","journal-title":"Vasc Health Risk Manag."},{"issue":"5","key":"63_CR16","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1111\/j.1742-1241.2008.01716.x","volume":"62","author":"A Ringborg","year":"2008","unstructured":"Ringborg A, Martinell M, Stalhammar J, Yin DD, Lindgren P. Resource use and costs of type 2 diabetes in Sweden\u2014estimates from population-based register data. Int J Clin Pract. 2008;62(5):708\u201316. \n                    https:\/\/doi.org\/10.1111\/j.1742-1241.2008.01716.x\n                    \n                  .","journal-title":"Int J Clin Pract"},{"issue":"6","key":"63_CR17","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/j.1464-5491.2008.02444.x","volume":"25","author":"AB Wirehn","year":"2008","unstructured":"Wirehn AB, Andersson A, Ostgren CJ, Carstensen J. Age-specific direct healthcare costs attributable to diabetes in a Swedish population: a register-based analysis. Diabet Med. 2008;25(6):732\u20137. \n                    https:\/\/doi.org\/10.1111\/j.1464-5491.2008.02444.x\n                    \n                  .","journal-title":"Diabet Med"},{"issue":"7","key":"63_CR18","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1007\/s00125-002-0859-9","volume":"45","author":"R Williams","year":"2002","unstructured":"Williams R, Van Gaal L, Lucioni C. Assessing the impact of complications on the costs of type II diabetes. Diabetologia. 2002;45(7):S13\u20137. \n                    https:\/\/doi.org\/10.1007\/s00125-002-0859-9\n                    \n                  .","journal-title":"Diabetologia"},{"issue":"5","key":"63_CR19","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.pcd.2015.01.001","volume":"9","author":"U Sabale","year":"2015","unstructured":"Sabale U, Bodegard J, Sundstrom J, Ostgren CJ, Nilsson P, Johansson G, et al. Healthcare utilization and costs following newly diagnosed type-2 diabetes in Sweden: a follow-up of 38,956 patients in a clinical practice setting. Prim Care Diabetes. 2015;9(5):330\u20137. \n                    https:\/\/doi.org\/10.1016\/j.pcd.2015.01.001\n                    \n                  .","journal-title":"Prim Care Diabetes."},{"issue":"5","key":"63_CR20","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1046\/j.1365-2796.2000.00749.x","volume":"248","author":"F Henriksson","year":"2000","unstructured":"Henriksson F, Agardh CD, Berne C, Bolinder J, Lonnqvist F, Stenstrom P, et al. Direct medical costs for patients with type 2 diabetes in Sweden. J Intern Med. 2000;248(5):387\u201396.","journal-title":"J Intern Med"},{"key":"63_CR21","volume-title":"Diabetes expenditure, burden of disease and management in 5 EU countries","author":"P Kavanos","year":"2012","unstructured":"Kavanos P, van den Aardweg S, Schurer W. Diabetes expenditure, burden of disease and management in 5 EU countries. London: LSE Health, London School of Economics; 2012."},{"key":"63_CR22","unstructured":"Socialstyrelsen. Nationell vikt 2014 slutenv\u00e5rd 2014. \n                    http:\/\/www.socialstyrelsen.se\/klassificeringochkoder\/norddrg\/vikter\n                    \n                  . Accessed 15 May 2017."},{"key":"63_CR23","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1186\/1471-2458-11-350","volume":"11","author":"TM Salopuro","year":"2011","unstructured":"Salopuro TM, Saaristo T, Oksa H, Puolijoki H, Vanhala M, Ebeling T, et al. Population-level effects of the national diabetes prevention programme (FIN-D2D) on the body weight, the waist circumference, and the prevalence of obesity. BMC Public Health. 2011;11:350. \n                    https:\/\/doi.org\/10.1186\/1471-2458-11-350\n                    \n                  .","journal-title":"BMC Public Health."},{"issue":"1","key":"63_CR24","doi-asserted-by":"publisher","first-page":"140","DOI":"10.2337\/dc14-2441","volume":"38","author":"SE Inzucchi","year":"2015","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140\u20139. \n                    https:\/\/doi.org\/10.2337\/dc14-2441\n                    \n                  .","journal-title":"Diabetes Care"},{"key":"63_CR25","unstructured":"Riksstroke. Riksstroke yearly report 2013\u2014acute stroke: The Swedish Stroke Registry. The Swedish Stroke Register; 2013. \n                    http:\/\/www.riksstroke.org\/wp-content\/uploads\/2014\/07\/Strokerapport_AKUTTIA3man_LR.pdf\n                    \n                  . Accessed 15 May 2017."},{"key":"63_CR26","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1186\/s12913-015-1139-y","volume":"15","author":"M Charokopou","year":"2015","unstructured":"Charokopou M, McEwan P, Lister S, Callan L, Bergenheim K, Tolley K, et al. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to metformin in the treatment of type 2 diabetes mellitus from a UK Healthcare System Perspective. BMC Health Serv Res. 2015;15:496. \n                    https:\/\/doi.org\/10.1186\/s12913-015-1139-y\n                    \n                  .","journal-title":"BMC Health Serv Res."},{"issue":"1","key":"63_CR27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.pcd.2014.04.007","volume":"9","author":"U Sabale","year":"2015","unstructured":"Sabale U, Ekman M, Granstrom O, Bergenheim K, McEwan P. Cost-effectiveness of dapagliflozin (Forxiga(R)) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Prim Care Diabetes. 2015;9(1):39\u201347. \n                    https:\/\/doi.org\/10.1016\/j.pcd.2014.04.007\n                    \n                  .","journal-title":"Prim Care Diabetes."},{"issue":"8","key":"63_CR28","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1177\/2047487316687860","volume":"24","author":"V Ritsinger","year":"2017","unstructured":"Ritsinger V, Hero C, Svensson AM, Saleh N, Lagerqvist B, Eeg-Olofsson K, et al. Mortality and extent of coronary artery disease in 2776 patients with type 1 diabetes undergoing coronary angiography: a nationwide study. Eur J Prev Cardiol. 2017;24(8):848\u201357. \n                    https:\/\/doi.org\/10.1177\/2047487316687860\n                    \n                  .","journal-title":"Eur J Prev Cardiol."},{"issue":"5","key":"63_CR29","doi-asserted-by":"publisher","first-page":"e0177476","DOI":"10.1371\/journal.pone.0177476","volume":"12","author":"TG Poder","year":"2017","unstructured":"Poder TG, Erraji J, Coulibaly LP, Koffi K. Percutaneous coronary intervention with second-generation drug-eluting stent versus bare-metal stent: systematic review and cost-benefit analysis. PLoS ONE. 2017;12(5):e0177476. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0177476\n                    \n                  .","journal-title":"PLoS ONE"},{"issue":"8","key":"63_CR30","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1093\/europace\/euu012","volume":"16","author":"L Guedon-Moreau","year":"2014","unstructured":"Guedon-Moreau L, Lacroix D, Sadoul N, Clementy J, Kouakam C, Hermida JS, et al. Costs of remote monitoring vs. ambulatory follow-ups of implanted cardioverter defibrillators in the randomized ECOST study. Europace. 2014;16(8):1181\u20138. \n                    https:\/\/doi.org\/10.1093\/europace\/euu012\n                    \n                  .","journal-title":"Europace."},{"issue":"11","key":"63_CR31","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.2337\/diacare.27.11.2616","volume":"27","author":"J Oliva","year":"2004","unstructured":"Oliva J, Lobo F, Molina B, Monereo S. Direct health care costs of diabetic patients in Spain. Diabetes Care. 2004;27(11):2616\u201321.","journal-title":"Diabetes Care"},{"issue":"3","key":"63_CR32","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2165\/00019053-199916030-00005","volume":"16","author":"SD Ramsey","year":"1999","unstructured":"Ramsey SD, Newton K, Blough D, McCulloch DK, Sandhu N, Wagner EH. Patient-level estimates of the cost of complications in diabetes in a managed-care population. Pharmacoeconomics. 1999;16(3):285\u201395.","journal-title":"Pharmacoeconomics."},{"key":"63_CR33","doi-asserted-by":"publisher","unstructured":"Clarke PM, Gray AM, Briggs A, Farmer AJ, Fenn P, Stevens RJ, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia. 2004;47(10):1747\u201359. \n                    https:\/\/doi.org\/10.1007\/s00125-004-1527-z\n                    \n                  .","DOI":"10.1007\/s00125-004-1527-z"},{"issue":"15","key":"63_CR34","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.2165\/00019053-200321150-00006","volume":"21","author":"JE Lavigne","year":"2003","unstructured":"Lavigne JE, Phelps CE, Mushlin A, Lednar WM. Reductions in individual work productivity associated with type 2 diabetes mellitus. Pharmacoeconomics. 2003;21(15):1123\u201334.","journal-title":"Pharmacoeconomics."}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s41669-017-0063-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-017-0063-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-017-0063-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T08:08:20Z","timestamp":1554192500000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s41669-017-0063-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,27]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["63"],"URL":"https:\/\/doi.org\/10.1007\/s41669-017-0063-y","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,27]]},"assertion":[{"value":"27 November 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The work was supported by AstraZeneca Nordic-Baltic.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"US and JB hold full-time positions at AstraZeneca. DN, JWE, TN, AN, and UO have received compensation for their work from AstraZeneca.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}